透云生物发布中期业绩，股东应占溢利1124.3万港元 同比扭亏为盈

Core Viewpoint - The company reported a significant improvement in profitability despite a decline in revenue, indicating a potential recovery in financial performance [1] Financial Performance - Revenue for the six months ending June 30, 2025, was HKD 36.581 million, a decrease of 20.82% year-on-year [1] - The profit attributable to the company's owners was HKD 11.243 million, a turnaround from a loss of HKD 47.969 million in the same period last year [1] - Earnings per share were HKD 0.004 [1] Factors Influencing Performance - The increase in profit was primarily due to the rise in fair value gains on financial assets measured at fair value through profit or loss [1]